Read the full blog article here: ms-perspektive.com – ECTRIMS 2025 MS Highlights ECTRIMS 2025 MS Highlights: First Insights for Patients ECTRIMS is the world's largest MS conference, and in 2025 it takes place in Barcelona. Thousands of researchers and clinicians share the newest findings on multiple sclerosis. In this episode, we look at the first highlights from the press releases: Early biomarkers for silent progression (PIRA) How menopause may influence MS and comorbidities The role of ultra-processed foods in relapses and MRI lesions Environmental risk: pediatric ozone exposure Ocrelizumab's strong relapse control—and its limits against progression Learn what this research could mean for you, why statistical significance isn't always clinical significance, and why these insights matter for the future of MS care. More iformation on: ectrims.eu/ectrims2025/ See you soon and try to make the best out of your life, Nele For more information and positive thoughts, subscribe to my newsletter for free. Click here for an overview of all podcast episodes published so far. 🔗 References For those who would like to dive deeper, here are the scientific abstracts presented at ECTRIMS 2025: PIRA biomarkers – Landwehr A., et al. Proteomic Signatures of PIRA: Distinct proteins in cerebrospinal fluid are associated with progression independent of relapse activity in multiple sclerosis. ECTRIMS 2025, Barcelona. Menopause and MS – Şimşek SY. Impact of Menopause on Initial Clinical Presentation and Comorbidities in Women with Multiple Sclerosis: A Comparative Study with Age-Matched Men. ECTRIMS 2025, Barcelona. Ultra-processed foods – Dalla Costa G. Association of Ultra-Processed Food Intake with Increased MS Disease Activity: Findings from the BENEFIT Trial. ECTRIMS 2025, Barcelona. Pediatric ozone exposure – Pugliatti M., Bergamaschi R., Pilotto A., Ghezzi A., et al. Exposure to ozone is associated with an increased risk of pediatric multiple sclerosis (pedMS): the PEDIGREE study. Abstract IMS25-LBA-176. ECTRIMS 2025, Barcelona. Ocrelizumab – Roos I. Real-world effectiveness of ocrelizumab in multiple sclerosis: a multi-registry observational cohort study. ECTRIMS 2025, Barcelona.

Ver todos los episodios